Home›Trial›NCT02057133
🔬NCT02057133Phase 1ACTIVE NOT RECRUITING

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Study Summary

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.

Conditions
Breast Neoplasms
Interventions / Drugs
LY2835219LetrozoleAnastrozoleTamoxifenExemestaneEverolimusTrastuzumabLY3023414FulvestrantPertuzumabLoperamideEndocrine therapy
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment198 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.865952+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.